Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm Golgi apparatus membrane Lipid-anchor Note=Shuttles between the cytosol and the Golgi apparatus. |
Domain |
PF12722 High-temperature-induced dauer-formation protein |
Function |
May play an important role in the development of cancers in a broad range of tissues. |
Biological Process |
GO:0031001 response to brefeldin A GO:0046677 response to antibiotic |
Molecular Function | - |
Cellular Component |
GO:0000138 Golgi trans cisterna GO:0005795 Golgi stack GO:0005797 Golgi medial cisterna GO:0005874 microtubule GO:0005881 cytoplasmic microtubule GO:0019898 extrinsic component of membrane GO:0031312 extrinsic component of organelle membrane GO:0031984 organelle subcompartment GO:0031985 Golgi cisterna GO:0090498 extrinsic component of Golgi membrane GO:0098791 Golgi subcompartment |
KEGG | - |
Reactome | - |
Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between HID1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of HID1 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of HID1 in various data sets.
|
Points in the above scatter plot represent the mutation difference of HID1 in various data sets.
|
Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HID1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HID1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HID1. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HID1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of HID1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between HID1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | HID1 |
Name | HID1 domain containing |
Aliases | HID-1; downregulated in multiple cancer 1; C17orf28; chromosome 17 open reading frame 28; HID1 domain-contai ...... |
Chromosomal Location | 17q25.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting HID1 collected from DrugBank database. |
There is no record. |